Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
European Medicines Agency completes review of Pandemrix
Notice type:
Advisory
Date:
21/07/2011
Product name or type:
Pandemrix
Problem Or Issue:
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has finalised its review of Pandemrix which was initiated to investigate a possible link between Pandemrix vaccination and narcolepsy. This followed an increased number of reported cases of narcolepsy among children and adolescents in Finland and Sweden.
While stressing that further research is necessary, the CHMP recommends that Pandemrix should only be used in people under 20 years of age if the recommended annual seasonal trivalent influenza vaccine is not available.
The overall benefit-risk balance of Pandemrix remains positive.
Background Information Or Related Documents:
European Medicines Agency completes review of Pandemrix Document
Further Information:
See
EMA Press Release
and
Q&A document
for further information.
« Back
Date Printed: 26/04/2024